The Supera peripheral stent occupies a unique class of stent technology. With the Supera stent’s ability to mimic the anatomy's natural movement while optimizing luminal gain, healthcare professionals find this vascular stent effective when treating the dynamic environment of the superficial femoral artery (SFA) and proximal popliteal arteries.

THE CLINICALLY PROVEN1 SUPERA STENT

When peripheral artery disease causes blockages in the SFA and popliteal arteries, the Supera stent can restore blood flow during a percutaneous transluminal angioplasty (PTA) procedure. Supera has been analyzed in over 1,600 patients worldwide.2

Innovative, Interwoven Nitinol Design

• Allows Supera to mimic the natural movement of the anatomy
• Supports the vessel with minimal chronic outward force3,4

Strength and Flexibility

• Provides unparalleled strength and flexibility, with more than four times the compression resistance of all other standard Nitinol stents5,6
• Has visible compression resistance in severely calcified lesions, maintaining a round, open lumen7

Clinical Efficacy

• 87.6% freedom from target lesion revascularization (TLR) in severely calcified lesions at 3 years (n = 325)8
• 86.3% primary patency (K-M) at 1 year3
• 0 fracture at 1 year; 1 fracture at 3 years8